Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:JSPR NASDAQ:KALA NASDAQ:NRXP NASDAQ:ONCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJSPRJasper Therapeutics$0.97-2.0%$1.09$0.62▼$7.19$27.06M3.07582,301 shs193,779 shsKALAKALA BIO$0.11+3.8%$0.24$0.10▼$20.60$104.20M-2.236.07 million shs2.10 million shsNRXPNRx Pharmaceuticals$3.04+1.3%$2.22$1.62▼$3.84$100.53M2.021.06 million shs1.33 million shsONCYOncolytics Biotech$0.92-1.4%$1.00$0.33▼$1.51$106.26M1.021.34 million shs1.54 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJSPRJasper Therapeutics0.00%+0.04%+35.22%-35.40%-82.80%KALAKALA BIO0.00%-8.71%-35.96%-76.81%-97.09%NRXPNRx Pharmaceuticals0.00%+1.98%+40.45%+51.47%+50.73%ONCYOncolytics Biotech0.00%-10.18%-9.39%-0.88%+58.20%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJSPRJasper Therapeutics$0.97-2.0%$1.09$0.62▼$7.19$27.06M3.07582,301 shs193,779 shsKALAKALA BIO$0.11+3.8%$0.24$0.10▼$20.60$104.20M-2.236.07 million shs2.10 million shsNRXPNRx Pharmaceuticals$3.04+1.3%$2.22$1.62▼$3.84$100.53M2.021.06 million shs1.33 million shsONCYOncolytics Biotech$0.92-1.4%$1.00$0.33▼$1.51$106.26M1.021.34 million shs1.54 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJSPRJasper Therapeutics0.00%+0.04%+35.22%-35.40%-82.80%KALAKALA BIO0.00%-8.71%-35.96%-76.81%-97.09%NRXPNRx Pharmaceuticals0.00%+1.98%+40.45%+51.47%+50.73%ONCYOncolytics Biotech0.00%-10.18%-9.39%-0.88%+58.20%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJSPRJasper Therapeutics 2.42Hold$19.881,956.81% UpsideKALAKALA BIO 2.00Hold$20.3818,075.74% UpsideNRXPNRx Pharmaceuticals 2.50Moderate Buy$38.251,158.22% UpsideONCYOncolytics Biotech 2.60Moderate Buy$8.50828.96% UpsideCurrent Analyst Ratings BreakdownLatest JSPR, NRXP, KALA, and ONCY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/27/2026NRXPNRx Pharmaceuticals Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$48.00 ➝ $49.004/27/2026NRXPNRx Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.004/24/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026JSPRJasper Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026NRXPNRx Pharmaceuticals D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.003/27/2026KALAKALA BIO Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/24/2026NRXPNRx Pharmaceuticals D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.003/24/2026NRXPNRx Pharmaceuticals BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.003/23/2026JSPRJasper Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral3/16/2026NRXPNRx Pharmaceuticals D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.00(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJSPRJasper TherapeuticsN/AN/AN/AN/A$0.15 per shareN/AKALAKALA BION/AN/AN/AN/A$0.71 per shareN/ANRXPNRx Pharmaceuticals$1.23M81.73N/AN/A($0.54) per share-5.63ONCYOncolytics BiotechN/AN/AN/AN/A($0.04) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJSPRJasper Therapeutics-$75.80M-$4.60N/AN/AN/AN/A-372.18%-153.67%5/11/2026 (Estimated)KALAKALA BIO-$26.98M-$3.33N/AN/AN/AN/A-12,971.16%-90.83%N/ANRXPNRx Pharmaceuticals-$28.62M-$1.39N/A2.47N/AN/AN/A-265.03%5/21/2026 (Estimated)ONCYOncolytics Biotech-$28.76M-$0.29N/AN/AN/AN/A-2,185.97%-243.94%5/13/2026 (Estimated)Latest JSPR, NRXP, KALA, and ONCY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026NRXPNRx Pharmaceuticals-$0.01N/AN/AN/A$25.57 millionN/A5/13/2026Q1 2026ONCYOncolytics Biotech-$0.05N/AN/AN/AN/AN/A5/11/2026Q1 2026JSPRJasper Therapeutics-$0.46N/AN/AN/AN/AN/A4/15/2026Q4 2025KALAKALA BIO-$0.17$0.86+$1.03$0.86N/AN/A3/30/2026Q4 2025JSPRJasper Therapeutics-$0.79-$0.3250+$0.4650-$0.32N/AN/A3/30/2026Q4 2025ONCYOncolytics Biotech-$0.06-$0.08-$0.02-$0.08N/AN/A3/23/2026Q4 2025NRXPNRx Pharmaceuticals-$0.09$0.19+$0.28$0.19$7.53 million$0.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthJSPRJasper TherapeuticsN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJSPRJasper TherapeuticsN/A2.622.62KALAKALA BION/A3.813.81NRXPNRx PharmaceuticalsN/A0.310.31ONCYOncolytics BiotechN/A1.121.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJSPRJasper Therapeutics79.85%KALAKALA BIO24.61%NRXPNRx Pharmaceuticals4.27%ONCYOncolytics Biotech6.82%Insider OwnershipCompanyInsider OwnershipJSPRJasper Therapeutics4.60%KALAKALA BIO2.24%NRXPNRx Pharmaceuticals6.40%ONCYOncolytics Biotech0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJSPRJasper Therapeutics2028.00 million26.71 millionOptionableKALAKALA BIO30929.49 million908.67 millionNot OptionableNRXPNRx Pharmaceuticals233.07 million30.95 millionOptionableONCYOncolytics Biotech30116.13 million116.01 millionNot OptionableJSPR, NRXP, KALA, and ONCY HeadlinesRecent News About These CompaniesOncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal CancerMay 4 at 9:00 AM | globenewswire.comOncolytics Biotech Inc. (NASDAQ:ONCY) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 1, 2026 | americanbankingnews.comOncolytics Biotech Inc. (NASDAQ:ONCY) Given Average Rating of "Moderate Buy" by AnalystsMay 1, 2026 | marketbeat.comOncolytics Biotech, Inc.: Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer StudyApril 27, 2026 | finanznachrichten.deOncolytics Aligns with FDA on Planned Pivotal Anal Cancer StudyApril 27, 2026 | globenewswire.comOncolytics Could Re-Rate As Pelareorep Focuses On Registrational PathsApril 25, 2026 | seekingalpha.comQ1 EPS Forecast for Oncolytics Biotech Lifted by AnalystApril 14, 2026 | marketbeat.comEquities Analysts Issue Forecasts for ONCY Q1 EarningsApril 13, 2026 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: ArriVent BioPharma, Inc. (AVBP) and Oncolytics Biotech (ONCY)April 12, 2026 | theglobeandmail.comQ1 Earnings Estimate for ONCY Issued By Zacks ResearchApril 9, 2026 | marketbeat.comWhat is Zacks Research's Forecast for ONCY FY2026 Earnings?April 8, 2026 | marketbeat.comOncolytics Plans FDA Meeting for Pelareorep SCAC StudyApril 7, 2026 | theglobeandmail.comONCY: Initiating Coverage of Oncolytics Biotech; A Focused Path to Unlocking the Potential of PelareorepApril 7, 2026 | msn.comOncolytics Biotech Establishes $75 Million ATM OfferingApril 6, 2026 | tipranks.comOncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal CancerApril 6, 2026 | globenewswire.comOncolytics Biotech Inc. (NASDAQ:ONCY) Receives Consensus Rating of "Moderate Buy" from AnalystsApril 6, 2026 | marketbeat.comOncolytics Biotech’s Nevada Move Resets Capital Access And Dilution Trade OffApril 1, 2026 | finance.yahoo.comOncolytics Biotech® Completes Domicile Change to the United StatesApril 1, 2026 | globenewswire.comThe Patent Cliff is Coming, Driving Smart Money Towards Precision OncologyMarch 19, 2026 | financialpost.comFOncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026March 19, 2026 | globenewswire.comJames Parsons Acquires 10,000 Shares of Oncolytics Biotech (NASDAQ:ONCY) StockMarch 14, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJSPR, NRXP, KALA, and ONCY Company DescriptionsJasper Therapeutics NASDAQ:JSPR$0.97 -0.02 (-1.98%) Closing price 04:00 PM EasternExtended Trading$0.98 +0.01 (+1.31%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.KALA BIO NASDAQ:KALA$0.11 +0.00 (+3.80%) Closing price 04:00 PM EasternExtended Trading$0.11 +0.00 (+0.80%) As of 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.NRx Pharmaceuticals NASDAQ:NRXP$3.04 +0.04 (+1.33%) Closing price 04:00 PM EasternExtended Trading$3.06 +0.02 (+0.82%) As of 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.Oncolytics Biotech NASDAQ:ONCY$0.92 -0.01 (-1.36%) Closing price 04:00 PM EasternExtended Trading$0.91 -0.01 (-0.77%) As of 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
